Molecular detection of enterotoxigenic *Escherichia coli* surface antigens from patients in Machakos District Hospital, Kenya

Juma BW\(^{1,5}\), Waiyaki PG\(^{1,3}\), Bulimo WD\(^{1,2,4}\), Wurapa EK\(^2\), Mutugi MM\(^1\), Kariuki S\(^{1,3}\)

**Abstract**

**Introduction:** Enterotoxigenic *Escherichia coli* (ETEC) is known for its public health importance globally, however, a protective vaccine is yet to be developed. Information regarding the immunology of ETEC’s virulence proteins that can lead to studies on vaccine development such as the heat stable toxins (ST), heat-labile toxin (LT), colonization factors (CFs) and coli surface antigens (CS) from many regions of the world is available. In Kenya, specific CFAs and CS have not been adequately characterized. This study looked at the surface antigens of diarrhoeagenic *E. coli* in search of indicators for vaccine materials development.

**Methodology:** Multiplex polymerase chain reaction assay were employed to detect diarrhoeagenic *E. coli* pathotypes and enterotoxigenic *Escherichia coli* surface antigens/colonization factors antigens from 300 patients in Machakos Hospital, Kenya.

**Results:** Enteroaggregative *Escherichia coli* was the most predominant (13.7%) followed by ETEC (11%), Enteroinvasive *E. coli* (8.3%) and Enteropathogenic *E. coli* (4.3%). Among the colonization factor antigens, CFAI was detected at 25 (23%), CS1, CSII 2(1.9%), CS3 1(0.9%), CS6 13(12%), CS7 2 (1.9%), CS12 1(0.9%), CS19 11 (10.25%) and those without colonization factor 37 (34.3%).

**Conclusions:** ETEC isolates carrying ST or STLT toxins had more recoverable CFs than those with LT alone (P<0.05). The CS6 is increasing and CS19 was detected for the first time in Kenya and shown to be persistent adhesins. These may be further investigated as possible candidates for the formulation of a novel vaccine for the prevention of diarrhoea in Kenya and the region.

**Key words:** Colonization factor antigens, Coli surface antigens, Multiplex Polymerase Chain Reaction, Enterotoxigenic *E. coli*.

**Introduction**

Enterotoxigenic *Escherichia coli* (ETEC) is one of *E. coli* pathotypes causing diarrhoea in children from developing countries and adults travelling from developed to developing countries [1]. ETEC is rated the second cause of diarrhoea after rotavirus in children under five years of age [2]. Ingestion of contaminated food and water is the main mode of transmission of ETEC [3]. The disease presents with vomiting and/or diarrhoea with or without dehydration [4]. Enterotoxigenic *E. coli* adheres and colonizes the lining of the intestines by use of specific fimbriae referred to as colonization factors or coli surface antigens (CFs) [1].

More than 25 human ETEC CFs have been described based on differences in their primary amino acid sequences of the adhesive fimbrial structural subunits [5]. This puts them in distinct families based on distinct fimbriae on the basis of their genetic diversity [5]. CFs have been divided into three families: (i) a CFAI-like group including CFA/I, CS1, CS2, CS4, CS14, CS17 and CS19; (ii) a CS5-like group including CS5, CS7, CS18, and CS20; and (iii) a unique group including CS3, CS6, and CS10 to CS12 [1]. The ETEC isolates may express a single detectable CF, for example, in CFAI or multiple CFs as seen in CS3 (CS3 alone or in combination with CS1 or CS2) and CS6 (CS6 alone or in combination with CS4 or CS5).

In Kenya several studies on the causes of diarrhoea have been carried out [6-8]. These studies have elaborated the existence of ETECs as causes of diarrhoea. However, they lacked the capability and tools to characterize the specific CFs within the ETEC isolates. To shed more light on circulating CFs, the current study sought to determine the prevalence of LT, ST, and ETEC CFs in patients from four months old and above in Machakos District Hospital.
Materials and Methods

Study patients: Study participants comprised of children from four months old and above from Machakos County seeking medical attention due to diarrhoea illness at the Machakos District Hospital, Kenya from September 2010 - September 2013. The study participants who had reached the age of consent gave informed consent and parents / guardians gave consent for their children to participate in the study. Research ethical approval was granted by the Ethical Review Committee of Kenya Medical Research Institute (KEMRI) SSC Number 989.

After the informed consent was voluntarily obtained, patients were examined and a questionnaire administered to collect each patient’s history and other demographic information.

Sample collection: Stool samples were collected in stool cups by the patients and immediately transferred to the Carry Blair medium by the technician and transported to Kenya Medical Research Institute’s Centre for Microbiology Research for culture and detection of enterotoxins and CFs. Children who could not provide stool samples had their rectal swabbed and placed in the Carry-Blair medium immediately for shipment to the laboratory in Kenya Medical Research Institute (KEMRI).

The samples were examined under a microscope, plated on MacConkey agar, and allowed to develop colonies. Five colonies of lactose fermenters (E. coli like in morphology) were picked and further tested using Triple sugar iron, motility, indole ornithine, and stored at -80°C for further analysis.

Bacteria identification: Samples were processed using standard microbiological techniques. Briefly, stool samples were plated on different freshly prepared and quality controlled media (MacConkey, Xylose lysine desoxycholate (XLD) and incubated at 37°C for 18-24 hours. They were then sub-cultured on nutrient agar. Different colonies from each media were selected as follows: Two to three colonies (black, medium and small size pink or clear) from XLD for suspected Salmonella spp and Shigella spp; 5-6 colonies (5-lactose and one non-lactose fermenter) from Lactose MacConkey for different E. coli pathotypes; both yellow and green colonies from TCBS for Vibrio cholerae and Vibrio parahemolyticus respectively, and one clear colony from Sorbital MacConkey to detect E. coli 0157:H7. Isolates confirmed as E. coli using TSI (A/A, -H,S, + gas), Simmon’s citrate (green), motile, and indole positive were confirmed for different E. coli pathotypes by multiplex polymerase chain reaction (mPCR).

Detection of E. coli pathotypes, ETEC CFAs and coli surface antigens: The DNA was extracted from E. coli by boiling. PCR was done in a 25-μL reaction mixture containing 5μL of boiled whole cell lysate, 100 μmol/L each deoxynucleoside triphosphate, 1× GoTaq Flexi DNA polymerase (Promega) as previously described [9].

Genetic relatedness of ETEC by PFGE: Genomic DNA of various strains of ETEC, were prepared in Agarose plugs as described by Kariuki et al. [10] from an overnight culture in Luria batani broth. For complete digestion of DNA, the XbaI (Life Technologies, Paisley, UK) enzymes were added following the manufacturer’s instructions. PFGE of agarose plug inserts was performed in the contour clamped homogenous electric field CHEF-DRIII (Bio-Rad Laboratories, Hercules, CA, USA) on a horizontal 1% agarose gel for 22 hours at 120V hours and pulse time of 1 to 40 sec at 14°C. A DNA (lambda ladder, Bio-Rad) consisting of 22 fragments of increasing size from 48kb -1000kb were used as the DNA size standard maker. The gels were stained with 0.05% ethidium bromide and observed on a gel Doc 2000 (Bio-Rad). Restriction endonuclease digest pattern of XbaI digest genomic DNA were compared and similarities as well as differences scored as described by Kariuki et al [11].

Statistical analysis: The data were analyzed using EpiInfo (version 3.4.3; Center for Disease Control and Prevention, Atlanta, Georgia). The Chi-square and Fishers’ Exact tests were used for comparisons between the groups.

Results

Between September 2010 to September 2013, 1600 isolates were cultured from 301 specimens from patients with diarrhoea attending Machakos District Hospital who ranged from the ages of 4 months to 85 years.

A total of 98 ETECS isolates were recovered from 33/300 patients among them 13 children below five years of age, 2 participants aged between 6 and 10 years and 18 subjects above the age of 16 years. We did not isolate any ETEC from the ages between 11 and 15 years. The ETEC isolates represented 11% of all E. coli pathotypes detected (56 LTs, 17 ST1, 19 ST2 and 6 LT / ST1 combined). The frequency of ETEC infection and the associated virulence traits were compared across the study period, and there was no statistical significant (P>0.05).

Distribution of ETEC colonization factor antigens by phenotype: The proportions of ETEC isolates expressing ST and LT in study subjects with diarrhoea were similar over the study period, with no seasonal variation. ETEC isolates expressing LT were isolated from similar proportions of cases during the first three quarters of the study. Similarly, ETEC isolates expressing ST were isolated from comparable proportions of ETEC diarrhoea episodes during the second quarter (40%; n = 48) and third quarter (43%; n = 47) but from a lower proportion during the fourth quarter of the study (20.1%; n = 21). The ETEC isolates expressing both LT and ST were recovered at the lowest frequency throughout the study.

To appreciate the diversity of the ETEC CFs obtained in our study, the expression of CFs for which specific oligonucleotide primer sequences are available were examined. In total, 46.9% (46/98) of the ETEC isolates expressed a detectable CF (Table 1). The most commonly expressed CF types were CFA/I (14.1%),...
CS6 (5.0%), CS14 (5%), CS7 (2%), and CS19 (9%). Many of CFs expressed by ETEC isolates expressing a CF were ST-associated. Minimal numbers CFs from LT ETECS were observed. A total of 48% of ETEC isolates that expressed an ST or LTST expressed a detectable CF (Table 1).

Table 1: Distribution of ETEC colonization factor antigens by phenotype

<table>
<thead>
<tr>
<th>CF type</th>
<th>ETEC toxin</th>
<th>LT</th>
<th>LT ST</th>
<th>ST</th>
<th>Mixed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>n=56(%)</td>
<td>n=6(%)</td>
<td>N=36(%)</td>
<td>n=10(%)</td>
</tr>
<tr>
<td>CFAI</td>
<td>9</td>
<td>50</td>
<td>42</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>CSI</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CS1+CS3</td>
<td>0</td>
<td>0</td>
<td>5.6</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CS2+CS3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CS3</td>
<td>0</td>
<td>0</td>
<td>2.8</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CS4+CS6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CS5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CS5+CS6</td>
<td>18</td>
<td>0</td>
<td>8.3</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>CS6</td>
<td>7</td>
<td>16.7</td>
<td>13.9</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>CS7</td>
<td>0</td>
<td>16.7</td>
<td>(2.8)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CS12</td>
<td>0</td>
<td>0</td>
<td>2.8</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CS17</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CS19</td>
<td>5</td>
<td>0</td>
<td>19.4</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>CS20</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>No CFs</td>
<td>61</td>
<td>16.7</td>
<td>2.7</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

Clinical presentation associated with ETEC isolates expressing CFA/I, CS5 plus CS6 and CS 19.

Table 2: Age range of patients infected with ETEC isolates expressing CFA1, CS5 plus CS6, CS6, CS14 and CS 19

<table>
<thead>
<tr>
<th>CF type</th>
<th>Age (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3mn-≤5</td>
</tr>
<tr>
<td>CFAI</td>
<td>8(33.3)*</td>
</tr>
<tr>
<td>CS5+CS6</td>
<td>3(12.5)</td>
</tr>
<tr>
<td>CS6</td>
<td>4(16.7)</td>
</tr>
<tr>
<td>CS14</td>
<td>2(8.3)</td>
</tr>
<tr>
<td>CS19</td>
<td>7(29.2)</td>
</tr>
</tbody>
</table>

Most CFs were recovered from participants below 5 years of age.

Clinical data | ETEC-CF expression
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CFA1</td>
<td>CS5/6</td>
</tr>
<tr>
<td>n=14(%)</td>
<td>n=6(%)</td>
</tr>
<tr>
<td>Hospitalisation</td>
<td>36</td>
</tr>
<tr>
<td>Dehydration</td>
<td>13</td>
</tr>
<tr>
<td>Vomiting</td>
<td>21</td>
</tr>
<tr>
<td>Temp&gt;38°C</td>
<td>71</td>
</tr>
<tr>
<td>Mucus in stool</td>
<td>36</td>
</tr>
<tr>
<td>Stomach cramps</td>
<td>21</td>
</tr>
</tbody>
</table>

expressing CFA/I, CS5 plus CS6, CS6, and CS19.

The demographic and clinical data for the subjects with ETEC-associated diarrhoea were grouped according to the CF that the isolate expressed. Overall, ETEC isolates expressing a CF were more commonly recovered from children less than five years of age (Table 2). In addition, CS6 and CS19-expressing isolates were more frequently identified in the stools of children ranging between one and five years of age ($X^2 = 21.65; P < 0.05$, Table 2).

Table 3: Clinical presentation and ETEC colonization factor antigens expression

Clinical presentation associated with ETEC isolates expressing CFA/I, CS5 plus CS6 and CS 19.

In the analyses of the clinical data and CF types, ETEC cases associated with other bacterial (Shigella spp, Salmonella spp), infections were excluded to avoid the analysis of data for subjects with overlapping symptoms due to the presence of other enteric pathogens. The lower proportion of hospitalization among subjects infected with ETEC isolates expressing CS6 and CS19 was not significant compared to the percentage of children infected with ETEC isolates expressing other CF types ($X^2 = 1.21; P>0.05$) (Table 3). Among the subjects infected with ETEC isolates expressing CFA/I, the percentage with dehydration (43%) noted was higher compared to the percentage among those infected with ETEC isolates expressing other CF types (Table 3). Visible mucus in the stool was also reported in subjects infected with ETEC
With the use of highly specific primers, a variety of CFs were amplified, and one CS type (CS19) that had neither been detected nor reported in Kenya was identified (Figure 1).

The ETEC isolates were shown to be similar as indicated by PFGE bands which were within one to three band variations (Figure 2).

**Discussion**

Enterotoxigenic *E. coli* is one of the common causes of diarrhoea in the developing countries. We detected ETEC at 11% of diarrhoeal cases which is significantly higher than in previous studies in Kenya where the prevalence was reported at 3% [6,13,14]. Considering the diversity of ETEC CFs obtained in studies by Zhi-Dong et al. [6], it is surprising that no CS6 and CS19 were detected. In Nigeria [12], ETEC was detected at a lower rate compared with those detected in previous Kenyan studies [8,13]. In Peru, a detection rate of 5.3% was realized [13]. Because of differences in the occurrences of ETEC, the implementation of immunoprophylactic measures for the control of ETEC diarrhoea, should first be assessed and variations in the phenotypic, genotypic, and pathogenic properties of the bacterium at hand be identified. It is worth noting that this is the first time that the presence of CS19 in ETEC in Kenya has been documented. Studies done elsewhere also showed that the detection of CS6 is increasing throughout the world [6,13-16]. In the present study, it was also noted that a significantly low recovery of ETEC strains expressing CS6 and CS19 compared with the frequency of isolation of ETEC strains expressing other CF types from children below five years was obtained. Similarly, the current study noted that the detection of CFA/I-expressing ETEC isolates appeared to be more associated with children below 5 years of age and this finding agrees with those obtained from studies conducted by Claudia in Brazil and Ireland [14], Shaheen et al. [5] in Egypt, Walker et al. [17] in Zambia, Hall et al. [18] in England and Peruski et al. [19] in Bangladesh.

The rates of recovery of ETEC and the identities of the CFs reported in this study are similar to those from longitudinal community-based epidemiological studies of ETEC in northern Egypt and hospital-based studies in other disparate locations, such as Indonesia [20,21] but differ with findings in Peru [13,16] where the recovery rate was 5.3%. The rates of identification of ETEC isolates expressing CS6 and CS19 were similar in the entire study implying that these two CFs are persistent in the population. This makes them ideal vaccine candidates for prevention of diarrhoea due to ETEC. CS1 and CS3 were detected at a rate of 5.6%. These findings indicate that ETEC isolates expressing CS6 are more likely to be recovered from children below 5 years of age. They were however, significantly less recovered than ETEC isolates expressing CFA/I in children less than 5 years of age. Other ETEC CF types, such as CS3 alone were infrequently recovered at 2.8%. A similar observation was reported in Argentina and Brazil [15,22]. On the other hand, this finding differs from the results obtained in Mexico [23], Bangladesh [24,25] and Egypt [3] where CS6 component was identified at a higher percentage. It should be noted that the prevalence of infection due to ETEC isolates expressing CS6 or CS19 has been increasing in the world [3,26-29].

The highest rate of recovery of ETEC isolates expressing a detectable CF was during the warm months. This finding is in agreement with observations made in Egypt [30,31]. It should also be noted that the recovery of ETEC isolates expressing CS6 or CS19 did not appear to
vary by season as other CFs. From Studies carried out in the Judea area of the West-Bank of Israel [32] and by Sizemore in Malawi [33] similar observations were made, implying that CS6 and CS19 are stable and are viable candidates for the development of a vaccine for prevention of diarrhea due to ETEC.

In the present study, there were ETEC isolates without detectable CF. This observation is in agreement with findings from work done in Egypt [5,28] and the Asian region [34]. In the latter studies, approximately 50% of the ETEC isolates identified lacked detectable CF expression based on either dot blot analysis or DNA hybridization assays [5,31,34]. The percentage of ETEC isolates where a CF was not detectable expressed LT and these results were in agreement with those obtained from studies that used genotypic detection methods [13,35-37]. The lack of an identifiable CF in ETECs may have been due to the loss of the plasmid harboring the CF genetic element, down regulation of the CF genes, a mutation within the genetic locus, or expression of a CF not covered by the mPCR panel [15]. To account for differences due to age or diarrhea markers associated with ETEC isolates expressing one of the five major CFs found, the corresponding patient’s demographic and clinical data were related according to the ETEC CF identified.

Although ETEC infection can cause profuse watery diarrhea with little or no fever or vomiting, previous reports of ETEC isolates recovered from hospitalized infants elsewhere found the infection to be commonly associated with fever and vomiting [5,14,38,45].

In the current study, 5.3% of the children below three years of age with ETEC infection suffered from dehydration. In addition, vomiting and fever were reported in children shedding ETEC strains. The observation of severe diarrhea symptoms for example, dehydration and the number of stools per day in some of the children may be attributed to the presence of strains that are more virulent due to the presence of additional virulence factors [39-41]. It could also be that the presence of severe diarrhoeal symptoms may be the result of an immunologically naïve child’s first encounter with an ETEC pathogen.

An age-dependent isolation rate has been observed for ETEC isolates expressing CFA1 and CSs, suggesting a naturally acquired immunity in older children [31] and this was reflected in the current study. Establishing that CFA1-expressing isolates also induce an age-dependent immunity in older children would corroborate the concept of immunoprophylaxis to ETEC infection [42-45]. In the current study, the decline in the rate of infection with ETEC isolates expressing CFA1 that was seen from the age of 10 years and above supports this idea and underlies the importance of developing an ETEC vaccine since the risk factors for acquiring ETEC infection are present among children up to one year of age [23,30,46]. Further studies are needed to obtain a more in-depth understanding of the naturally acquired ETEC antifimbrial immune responses. In vitro experiments have demonstrated that environmental components have an impact on the expression of ETEC virulence factors [47].

In summary, ETEC was isolated more from children below the age of five years compared to those aged above 5 years. The increasing rates of ETEC strains expressing CS6 and the first time detection of CS19 was noted in Machakos County, Kenya. This calls for the need to increase surveillance of ETEC CFs. The information obtained will provide more understanding and characterization of more ETECs and ETECs CFs/CS that may be included in a potential Kenyan-based vaccine development for the control of diarrhea.

Acknowledgements

The authors would like to thank the employees of Centre for Microbiology Research, Kenya Medical Research Institute (KEMRI) for their cooperation during the study period. We would also like to thank the Director, KEMRI for allowing us to publish this work. Thanks to the US Army Medical Research Unit-Kenya for providing funds to carry out the project.

Conflict of interest: No conflict of interest is declared.

References


